Encellin raises about $10M for type 1 diabetes cell replacement therapy

Katherine Lewin

News Reporter

Encellin raised $9.9 million to join the burgeoning type 1 diabetes space with its own cell replacement therapy and first-in-human data expected next year. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Encellin raises about $10M for type 1 diabetes cell replacement therapy

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

En­cellin rais­es about $10M for type 1 di­a­betes cell re­place­ment ther­a­py

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Encellin raises about $10M for type 1 diabetes cell replacement therapy